SCHEMBL4838432

SCHEMBL4838432

COc1ccc(-c2nnc(Cl)c3cc(OC)cc(OC)c23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 3/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ALOX12 P18054 1/20 0.41
NTSR1 P30989 1/20 0.41
HTT P42858 1/20 0.41
PAX8 Q06710 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TLR9 Q9NR96 1/20 0.41
CASP1 P29466 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122604 0.79 PDE4A (0.47) KMT2APOLBKDM4EALDH1A1MAPT
SCHEMBL31359827 0.74 NPSR1 (0.57) KMT2AKDM4EALDH1A1MAPTHTT
SCHEMBL1396133 0.74 NPSR1 (0.57) KMT2AKDM4EALDH1A1MAPTHTT
SCHEMBL4834009 0.74 DHODH (0.48) KMT2APOLBKDM4EALDH1A1GAA
SCHEMBL4834600 0.74 ALDH1A1 (0.49) KMT2APOLBALDH1A1MAPTHTT
SCHEMBL4133994 0.74 DPP4 (0.41) KMT2APOLBKDM4EALDH1A1GAA
SCHEMBL4841379 0.73 CA1 (0.46) ABCB1KDM4EALDH1A1MAPTALOX12
SCHEMBL4834709 0.72 CNR1 (0.45) KMT2APOLBKDM4EALDH1A1MAPT
SCHEMBL4834418 0.72 CNR1 (0.45) KMT2APOLBKDM4EALDH1A1MAPT
SCHEMBL4843787 0.72 CYP3A4 (0.44) KDM4EALDH1A1GAAHTTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 ABCB1 565/4885KMT2A 1683/4885POLB 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.